SOHO 2024 | The in-depth responder analysis from PhALLCON: ponatinib versus imatinib
Josep-Maria Ribera, MD, PhD, Institut Català d’Oncologia Badalona, Barcelona, Spain, discusses the Phase III PhALLCON trial (NCT03589326), comparing the combination of reduced-intensity chemotherapy with either ponatinib or imatinib in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Ponatinib had a superior complete molecular response (CMR) rate and prolonged progression-free survival (PFS), and there was no significant difference in event-free survival (EFS). This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
